A Cervical Cancer Prevention Program Kenya: Overcoming Obstacles to Care, Promoting Understanding of HPV Natural History — Merck-3  

Cervical Cancer Clinical Trial

Official title: A Community-based Cervical Cancer Prevention Program in Kenya: Overcoming Obstacles to Care, Promoting Understanding of HPV Natural History

Status Not yet recruiting

Clinical Trial Summary

Cervical cancer is caused by oncogenic, or "high-risk" (HR) human papillomavirus (HPV), and is the main cause of cancer-related death among Kenyan women. This malignancy is theoretically preventable through a combination of screening of adult women and treating those with cervical premalignancies and vaccination of children and adolescents against HPV infection. However, only 5% of Kenyan women are regularly screened, and only 14% have ever been screened, which in Kenya is done by a method known as Visual Inspection with Acetic Acid (VIA). Possible obstacles to current screening include long travel to clinics, high costs, poor sensitivity and specificity of VIA, the need for extensive training for VIA, variability among providers in their interpretation of VIA, lack of trained personnel, and others. In addition, while safe and effective HPV vaccines have been available for 15 years, very few (<1%) Kenyan children and adolescents have been vaccinated. Obstacles to vaccination include high costs, poor delivery infrastructure, lack of education, long travel to clinics, and others. The investigators began a community-based program to develop a framework for eradication of cervical cancer by screening adult women and vaccinating female children. This program is becoming accepted in the Webuye region of Western Kenya, but there is still a great deal to learn. Going forward, this initiative will be known as the Kenya Mother-Daughter Cervical Cancer Eradication Program, or the Mother-Daughter Program (MDP) for short. The investigators propose a continuation of the MDP that will allow them to accumulate additional data needed to solidify the overall project and to answer additional questions as described below. To accomplish this goal the investigators will first enroll an additional 300 adult women to the program. This will increase the strength of the analysis of HR-HPV testing in detecting premalignant lesions of the cervix, especially in HIV-infected women. Second, the investigators will identify the positive and negative features of the MDP from the viewpoint of both the adult women and the girls enrolled in the program. Third, because anogenital warts (AGWs) may serve as a reservoir for HR-HPV, especially in women living with HIV/AIDS, the investigators will examine the prevalence, HPV type distribution, and treatment of these lesions among adult women participating in the MDP.

Clinical Trial Description

Project Framework The investigators will utilize a modification of the basic framework developed for the previous MISP (Merck Investigator-Initiated Studies Program) grant that began in 2018. This framework was successfully implemented in a rural Kenya community setting, and combines screening of adult women (ages 30 through 55) using HPV DNA testing of self-vaginal swabs with HPV vaccination of daughters (ages 9 through 14 years) of mothers attending community meetings. Rationale for conducting the proposed study Strategies based on centralized care have been unsuccessful in preventing cervical cancer in Kenyan women. HR-HPV DNA testing of self-collected vaginal swabs is acceptable and feasible, and the investigators have now shown that such testing can occur in a community setting in rural Kenya; other groups have demonstrated similar successes in Africa. In studies funded by MISP awards, the investigators have shown that essentially all women invited to community meetings agreed to enroll in the studies, to receive education about cervical cancer, and to provide a self-collected vaginal swab for HR-HPV DNA testing. Nearly all women who attended the community meetings were willing to have their female children vaccinated against HPV. The investigators have also shown that HPV vaccine can be delivered to western Kenya and can be administered to girls in a community setting. The investigators wish to continue to use this framework in the next MISP to further study the utility of this strategy and to address research questions that will elucidate the barriers to participation and will begin to provide information about the impact of the program. The reasons the investigators want to enroll additional women are as follows: First, the investigators would also like to evaluate the educational aspect of the Mother-Daughter Project among women and girls regarding to cervical cancer awareness and prevention knowledge. Second, the investigators would like to intensively study the acceptability of the community-based program, and define the obstacles of the program among women who are newly enrolled. The investigators will interview women and randomly selected children, and ask them to fill out detailed questionnaires related to these issues. Second, although the investigators expected to be able to address the issue of sensitivity and specificity of HR-HPV testing compared to VIA in the first MISP (MISP-I), the investigators noted an unexpectedly low rate of abnormal VIA in the original 200 women cohort. The second cohort of 300 women is still undergoing evaluation and the investigators do not yet know the incidence of abnormal VIA examinations. Thus, additional women need to be enrolled in a third wave to address this important question. Third, this program has benefited the community by providing a cancer prevention program that includes HPV vaccination, to which they have previously not had access to. This program has engendered trust between the local population and caregivers. Lastly, the investigators hope to submit a larger application to an organization such as the Gates Foundation or the NIH for a larger award of several years duration, based on as much preliminary data as can be generated from this project. The same rationale applies to our desire to vaccinate additional girls via the MISP mechanism. The investigators have vaccinated 2000 girls to date and as part of the second MISP (MISP-II). Because aflatoxin exposure represents a potential public health problem that could thwart efforts to control HPV-associated malignancies, the investigators will study the serological response to vaccination in girls with chronic aflatoxin exposure, once they have completed the vaccine regimen. The investigators will study the prevalence, HPV type distribution, and treatment response of AGWs in adult women living in Kenya. AGWs cause considerable morbidity in women, especially those who are HIV-infected. Few comprehensive studies are available in women living in sub-Saharan Africa. The investigators and others have previously showed that HR-HPV are frequently detected in AGWs from immunosuppressed people in the United States, including some people living with HIV. The investigators will determine the prevalence of AGWs in women participating in the community based program and test the hypothesis that the prevalence of AGW will be considerably higher in HIV-infected women. The investigators will also test the hypothesis that HR-HPV types will be frequently detected in AGW from HIV-infected women, suggesting that AGWs are a reservoir for HR-HPV and transmission. The investigators will also explore an objective related to treatment of AGWs to determine if a higher failure rate in HIV-infected women may be related to poor control of HIV (a higher HIV viral load) and detection of HR-HPV in the AGWs. Thus these aims build on the infrastructure the investigators have created in the first two MISP award cycles. The investigators believe the MDP, a community based approach to cervical cancer, can become the standard for western Kenya, act as a framework for HPV-associated cancer control, and can lead to a significant improvement in patient care as well as providing an opportunity for hypothesis driven research. The investigators propose a hypothesis driven study that expands our novel community-based approach to cervical cancer eradication in Kenya. The investigators plan to enroll 300 additional Kenyan women between the ages of 30 to 55 years. Self-collected vaginal swabs will be collected during the Community Meetings. Swabs will be tested for HR-HPV DNA at Moi University using the Roche Cobas Assay. Only women who have not previously participated in MISP I or II will be enrolled. All women will be asked to travel to the Webuye Clinic for VIA and pelvic examination, including careful inspection for AGWs. Regardless of HIV status, women with an abnormal ("positive") VIA will undergo four-quadrant punch biopsy of the cervix; 20% of women with normal ("negative") VIA will also undergo cervical biopsy so that the sensitivity and specificity of HR-HPV testing and VIA can be determined using histologically proven CIN 2/3+ as the gold standard. The investigators will enroll 2000 girls, ages 9 through 14 into the study and administer the HPV vaccine at the community meetings. The investigators have shown that vaccination is feasible in the community setting. In the new study, all women and girls will be asked to fill out questionnaires that will provide data about the educational aspects and overall acceptability of the MDP, and obstacles related to its initiation. In addition, approximately 10% of women and girls will be interviewed at the end of the study to gain insights into the acceptability of the community-based program compared to the traditional methods of screening and vaccination. The investigators wish to include the opinions and desires of the mothers and daughters in designing larger programs in the future. This MISP, if funded, will help to build on current experiences as well as answering specific questions related to the hypotheses the investigators have proposed. Study strategies of the Mother Daughter Project (MDP) Webuye is a community located in the western region of Kenya, in Bungoma County on the highway to Uganda. The total population of Webuye sub-county is approximately 25,000; it is estimated that there are approximately 5,000 to 6,000 women between the ages of 30 and 55 years. A "community entry strategy" has been utilized to introduce the prior studies and to invite women to community meetings. Prior to study initiation, a female Kenyan Counselor was trained about cervical cancer, how to educate women about this malignancy, and how to instruct women in performance of self-collected swabs. Village chiefs, village elders, women deemed to be community leaders, and leaders of the local churches were then approached by the Counselor and Study Coordinator to discuss the goals, strategy, and risks and benefits of the study. Discussions have focused on the importance of early screening for cervical cancer, the use of self-collected swabs for screening, and vaccination of children against HPV. Community meetings and self-collected vaginal swabs The Counselors will invite local women ages 30 through 55 years and their 9 through 14 year-old daughters/grand-daughters to meetings in Webuye. These meetings have been very successful; approximately 30 to 40 women attend each meeting, and many bring their daughters as well. The instructional brochure that the investigators developed for the proper self-collection method (available in both English and Swahili) will again be shared with participants. Women will obtain the swab in a private setting at the meeting. Self-collected swabs will be gathered by the Counselor, then a delivery person will transport the swabs (dry, no added medium) at ambient temperature to Moi Teaching and Referral Hospital (MTRH) laboratories in Eldoret, Kenya (about 60 km away). Swabs will be tested for HR-HPV DNA using the Roche Cobas Assay, a test that provides specific HPV 16 or 18 detection as well as detection of any of 12 additional oncogenic types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68). Results of the Cobas Assay will be entered into a RedCap database that the investigators previously created for the first MISP. Results of the Roche Cobas Assay will be delivered electronically to the Counselor's tablet, who will discuss these results with women at subsequent community meetings. VIA and cervical biopsy All women will be asked to go to the Webuye Clinic for VIA, which is the current standard of care for cervical cancer screening in Kenya. Regardless of HIV status, women with an abnormal ("positive") VIA will undergo four-quadrant punch biopsy of the cervix; 20% of women with normal ("negative") VIA will also undergo cervical biopsy. All women with abnormal VIA examinations will then be treated according to established local algorithms. In the event of suspected cancer, the participant will be sent to the Gynecologic Cancer Clinic at MTRH. In our vision for the future, women will be triaged to the local clinic for VIA only if they have a positive Cobas Assay, taking advantage of the high (>99%) negative predictive value of the Cobas Assay previously established in studies of HIV-uninfected women in the U.S.A., where the test is now FDA-approved for primary cervical cancer screening. However, the Roche Cobas Assay has not been adequately tested in HIV-infected women living in any country, or in HIV-uninfected women living in sub-Saharan Africa utilizing self-collected vaginal swabs. Biopsy of AGWs A pelvic examination will be performed, and AGWs (vulvar, introital, vaginal, perineal, perianal) will be identified by clinical inspection. A detailed anatomical chart will be utilized to document the location and size of suspected AGWs. Women with lesions suspicious for AGW will be scheduled for gynecologist review. If the gynecologist believes the lesions are consistent with AGW, he/she will perform excision biopsy under local anesthesia with 1% lidocaine injected into the base of the lesion. The entire lesion will be removed if smaller than 5 mm in diameter, and the remaining lesions will be treated with cryotherapy, per Kenya standard. Following cleansing of the affected area, lidocaine 1% will be injected into the base of the AGW, the excision will be performed with sterile instruments, generally scissors. The sample will be place in buffered formalin and sent to the Pathology Department at Moi University, where paraffin-embedded sections will be prepared. One section from each biopsy specimen will be stained with hematoxylin and eosin for histological confirmation, and additional sections will be used for DNA in situ hybridization assays (Dako Laboratories or another suitable system) using either a combined HPV 6/11 probe mix, an HPV 16/18 probe mix, or an HPV 31/33/35/39/45/52/58 probe mix. Sections will be scored positive or negative for each of the three probe mixes. This work will likely be performed at Indiana University School of Medicine, Indianapolis, IN, unless the investigators can train technicians at Moi University in this methodology. Follow-up visits for AGWs and cervical cancer screening Women in the study who have AGWs biopsied and treated will be asked to return in six months to the Webuye Clinic to determine if warts have recurred. Women will be asked to return to the Webuye Clinic for cervical cancer screening in one year if HIV-infected or in three years if HIV-uninfected. HPV vaccination of girls enrolled in the study Women will be instructed at the community meetings in the efficacy, safety and potential adverse effects of HPV vaccination. Vaccination against HPV will be offered to girls (2000 in all) ages 9 through 14 of women attending the community meetings. The second dose of the HPV vaccine will be administered six to twelve months after the first dose at subsequent community meetings. Careful records will be kept, and all families will be given a record of the vaccine administration. This is especially important because Kenya began a facility-based HPV vaccine program for 10 year-old girls in 2019, but few girls have been vaccinated to date. Our approach is important because many girls will not be able to attend school to receive the vaccine, or have the means to travel to local facilities for vaccination; it is therefore important that community-based opportunities for vaccination are an option in Kenya. In addition, the government program vaccinates girls at age 10 and does not include 9-year-olds so our project will be important for these girls. Questionnaires A detailed questionnaire (in Swahili and English) will be developed to 1) determine knowledge and beliefs of mothers about HPV and cervical cancer, which will be administered at the beginning of the study and at the end of the study, and 2) capture the opinions of mothers and daughters regarding all aspects of the program. Mothers will be asked about the self-collected swabs, travel to community meetings and the Clinic, acceptability of HPV vaccination of daughters. Daughters will be asked to answer questions related to vaccination; how the community-based approach compared to a school-based program, and other questions. Children will fill out the questionnaire with help from their mothers. The aims of this project will be accomplished during a two-year period. Key personnel will be trained in the first four months of the project. The remainder of the first year, and the second year will be devoted to community meetings, vaccinations, and VIA examinations, AGW biopsy and treatments, and follow up visits. The investigators (Drs. Brown, Ermel, Tong, Tonui, and Omenge) will be responsible for analyzing the study data. Sample size consideration and analysis plan for Objective 1: Determine if High-Risk (HR)-HPV DNA testing of self-collected vaginal swabs, collected in a community setting can be used as a triage step cervical cancer screening in HIV-infected Kenya women. Hypothesis: HIV-infected women with negative HR-HPV DNA tests uniformly have either 1) normal VIA examinations, or 2) falsely abnormal VIA examinations. The investigators will evaluate HR-HPV DNA testing of self-collected vaginal swabs as a triage step for VIA among HIV-infected rural Kenyan women. Our hypothesis is that HIV-infected women with negative HR-HPV DNA tests will have normal VIA examinations or falsely-abnormal VIA examinations (all women with abnormal VIA exams will undergo cervical biopsy). Sample size consideration: The investigators will enroll 300 adult women in this study. The investigators expect 30% (90 women) to be HIV-infected. Of the 90 HIV-infected women, the investigators expect 39% (35 women) to have a positive HR-HPV DNA test and 61% (55 women) to have a negative HR-HPV DNA test, based on the data from the pilot study. Of the 35 women with a positive HR-HPV DNA test, the investigators expect that 30% (11 women) will have an abnormal VIA, and of these 11 women, 50% (6 women) will have biopsy proven CIN2/3+. Of the 55 women with a negative HR-HPV DNA test, the investigators expect that 4% (2 women) will have an abnormal VIA, and of these 2 women, 1 woman will have biopsy proven CIN 2/3+. Thus, the investigators expect among 90 HIV-infected women, 17% women with positive HR-HPV DNA tests and 2% women with negative HR-HPV DNA tests will have biopsy proven CIN2/3+. To analyze the test characteristics of HPV DNA testing of self-collected vaginal swabs, the investigators will combine the data from the proposed sample of 300 women with the sample of 300 women that has been enrolled in the MISPII to a total sample of 600 women to test this hypothesis. The enrollment and HPV DNA testing procedures are identical between the two studies, which allows us to merge the two study populations to increase statistical power. Of the 600 women, the investigators expect 180 (30%) women to be HIV-infected. Among the 180 HIV-infected women, the investigators expect 70 women (39%) to have a positive HR-HPV DNA test and among them 17% (12 women) to have biopsy proven CIN2/3+, and 110 women (61%) to have a negative HR-DNA test and among them 2% (2 women) to have biopsy proven CIN2/3+. Our proposed sample size of 180 HIV-infected women (90 HIV-infected women from the current proposed sample of 300 women plus 90 HIV-infected women from the already enrolled 300 women in the MISP-II) will provide 89% power to detect a significant difference in biopsy-proven (CIN2/3+) VIA abnormality between HR-HPV DNA positive and HR-HPV DNA negative HIV-infected women at a two-sided 0.05 significance level based on Fisher's exact test. The investigators are requesting the HPV vaccine to vaccinate 2000 girls ages 9 through 14; two doses of vaccine will be required. Thus, the investigators request 4000 vaccine doses. Injection Site Reactions The protocol team should be contacted within 24 hours for any Grade 3 or 4 adverse experiences (AE) (e.g., injection site reactions, elevated temperatures following vaccination that occur at any point during study participation) thought definitely, possibly, or probably related to vaccination. Further vaccines should not be given to that participant prior to consultation with the Site Co- Investigator, Dr. Omenge Orang'o, phone number 0722 609132. For injection reactions judged to be life-threatening, the protocol team should be notified immediately. The person receiving the vaccine should be brought to a clinic immediately for evaluation and treatment. No additional vaccinations shall be given to that participant. Other Adverse Events The following guidelines will be used for the management of AEs that are felt to be at least possibly related to vaccines: - Grade 1 or 2 Toxicity/AE Participants who develop a Grade 1 or 2 AE may continue study vaccine. If a participant experiencing a Grade 1 or 2 AE chooses to permanently discontinue study treatment or study participation, the AE will be documented. - Grade 3 or 4 AE Participants who develop a Grade 3 or 4 AE that is at least possibly related to vaccine should be reevaluated for that toxicity until the AE returns to Grade ≤2. The study vaccine may be given at the discretion of the site investigator. If the same Grade 3 or 4 AE recurs and is considered by the investigator to be possibly, probably, or definitely related to the study vaccine, the study vaccine will be permanently discontinued. If, in the investigator's opinion, the AE has NOT been caused by the study vaccine or if the event is an asymptomatic laboratory abnormality, study treatment may continue. Cryotherapy- and LEEP (loop electro-excisional procedure)-Related Complications These complications will be documented and reported to the PIs as well as Merck. A brief summary of treatment for these complications is provided below. Vaginal Bleeding Bleeding post cervical biopsy will first be controlled with direct pressure using a dry swab. If this is not sufficient, then a swab with Monsel's solution will be applied to stop the bleeding. When postoperative bleeding occurs, it usually appears 4-6 days after treatment and often from the posterior lip of cervix. This bleeding can usually be controlled in the clinic by fulguration, applying Monsel's paste, or using a silver nitrate applicator stick. Rarely, placement of a suture at the bleeding site is necessary. The risk of post-treatment infection is very small and can likely be reduced even more by delaying surgical treatment until any woman with a likely diagnosis of pelvic inflammatory disease, cervicitis, vaginal trichomoniasis, or bacterial vaginosis has been adequately treated and recovered. Vaginal Infection The chance of postoperative infection is lessened by (1) only performing cryotherapy or LEEP when there is no evidence of bacterial STIs (sexually transmitted infections) and (2) advising women to abstain from vaginal intercourse for 6 weeks post procedure. In addition, participants are to be advised of the symptoms of infection and encouraged to return to the clinic if the symptoms occur. If a participant presents postoperatively with a malodorous discharge, it should be cultured if possible and empirical treatment prescribed with antibiotics that are effective for pelvic inflammatory disease. ;

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

• NCT number: NCT06411938
• Study type: Interventional
• Source: Indiana University
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2024
• Completion date: May 2026